Literature DB >> 21738361

Seroepidemiologic survey of varicella-zoster virus in korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test.

Yun Hwa Kim1, Ji Young Hwang, Kyung Min Lee, Jin Hee Choi, Tae Yoon Lee, Jong Soo Choi, Ho Sun Park.   

Abstract

BACKGROUND: Herpes zoster (HZ) occurs mainly in the elderly and Korea is rapidly becoming an aging society. Therefore, it is important to know the immune status against varicella-zoster virus (VZV) in Korean adults to prevent the disease.
OBJECTIVE: The aim of this study was to survey the immune status of Korean adults over 40 years of age against VZV.
METHODS: Antibody titer was measured using a VaccZyme™ VZV glycoprotein enzyme immunoassay (gpEIA) (Binding Site, UK). Fluorescent antibody to membrane antigen (FAMA) test was performed to measure the seropositive rate.
RESULTS: HZ incidence in the 214 adults enrolled in this study was 10.3%. The gpEIA geometric mean titer (GMT) was 490 mIU/ml and 90.2% of the subjects had a protective level of gpEIA antibody titer against varicella. The average gpEIA GMT of adults who previously had HZ was 1,122 mIU/ml, which was higher than the average gpEIA GMT of 457 mIU/ml in adults who had not had HZ. The FAMA positive rate was 98.6%.
CONCLUSION: Most (90.2%) Korean adults ≥40-years-of-age have a protective level of gpEIA antibody against varicella and 98.6% were FAMA seropositive. The GMT of gpEIA antibody was significantly increased with age, and was higher in adults with a history of HZ.

Entities:  

Keywords:  Glycoprotein enzyme immunoassay; Herpes-Zoster; Seroprevalence

Year:  2011        PMID: 21738361      PMCID: PMC3119997          DOI: 10.5021/ad.2011.23.1.39

Source DB:  PubMed          Journal:  Ann Dermatol        ISSN: 1013-9087            Impact factor:   1.444


  14 in total

1.  THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS.

Authors:  R E HOPE-SIMPSON
Journal:  Proc R Soc Med       Date:  1965-01

2.  Antibody assays suitable for assessing immune responses to live varicella vaccine.

Authors:  P J Provost; D L Krah; B J Kuter; D H Morton; T L Schofield; E H Wasmuth; C J White; W J Miller; R W Ellis
Journal:  Vaccine       Date:  1991-02       Impact factor: 3.641

3.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

4.  Population-based study of herpes zoster and its sequelae.

Authors:  M W Ragozzino; L J Melton; L T Kurland; C P Chu; H O Perry
Journal:  Medicine (Baltimore)       Date:  1982-09       Impact factor: 1.889

5.  Racial differences in the occurrence of herpes zoster.

Authors:  K Schmader; L K George; B M Burchett; C F Pieper; J D Hamilton
Journal:  J Infect Dis       Date:  1995-03       Impact factor: 5.226

6.  The incidence of herpes zoster.

Authors:  J G Donahue; P W Choo; J E Manson; R Platt
Journal:  Arch Intern Med       Date:  1995 Aug 7-21

Review 7.  Cell-mediated immunity to varicella-zoster virus.

Authors:  A M Arvin
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

8.  Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Rafael Harpaz; Ismael R Ortega-Sanchez; Jane F Seward
Journal:  MMWR Recomm Rep       Date:  2008-06-06

9.  Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine.

Authors:  M J Levin; M N Oxman; J H Zhang; G R Johnson; H Stanley; A R Hayward; M J Caulfield; M R Irwin; J G Smith; J Clair; I S F Chan; H Williams; R Harbecke; R Marchese; S E Straus; A Gershon; A Weinberg
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

10.  A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.

Authors:  Barbara P Yawn; Patricia Saddier; Peter C Wollan; Jennifer L St Sauver; Marge J Kurland; Lina S Sy
Journal:  Mayo Clin Proc       Date:  2007-11       Impact factor: 7.616

View more
  7 in total

1.  Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine.

Authors:  Lidao Bao; Guomin Wei; Hongmei Gan; Xianhua Ren; Ruilian Ma; Y I Wang; Haijun Lv
Journal:  Exp Ther Med       Date:  2016-02-19       Impact factor: 2.447

2.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

3.  Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test.

Authors:  S B Han; K R Kang; D H Huh; H C Lee; J H Kim; J H Kang; S H Ma
Journal:  Epidemiol Infect       Date:  2014-09-19       Impact factor: 2.451

4.  Sero-Prevalence of Antibodies against Varicella Zoster Virus in Children under Seven-Years Old in 2012 in Tehran, Iran.

Authors:  Yasaman Vojgani; Saeed Zarei; Samira Rajaei; Leili Chamani-Tabriz; Fatemeh Ghaemimanesh; Nematallah Mohammadinia; Mahmood Jeddi-Tehrani
Journal:  Iran J Public Health       Date:  2014-11       Impact factor: 1.429

Review 5.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

Review 6.  Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.

Authors:  Sung-Yeon Cho; Hyeon-Jeong Lee; Dong-Gun Lee
Journal:  Korean J Intern Med       Date:  2018-02-27       Impact factor: 2.884

7.  Seroepidemiology of varicella-zoster virus in Korea.

Authors:  Hyunju Lee; Hye Kyung Cho; Kyung-Hyo Kim
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.